Ratio Therapeutics, Inc.is on a mission to address a broad range of solid tumors through the development of therapeutic and imaging products based on two unique technologies, one of which has already garnered big pharma attention.
Ratio To Fine-Tune Radioligand Approach In Cancer With Trillium And Macropa Platforms
Emerging Company Profile: The US biotech’s Trillium platform, which has caught the eye of Bayer, could enhance radioligand pharmacokinetics and bioavailability while reducing side effects, enabling the development of both therapeutics and imaging compounds.
More from Emerging Company Profiles
• By
Emerging Company Profile: CEO Sean Ainsworth spoke with Scrip about how the company is developing B-cell therapies to treat a range of diseases, starting with MPS I.
• By
Emerging Company Profile: Resalis will soon start human trials of an oligonucleotide targeting a microRNA that is overexpressed in obese mice, but much remains to be proven in humans.
• By
Emerging Company Profile: Volastra is testing two KIF18A inhibitors in early clinical trials in ovarian cancer, backed by investors like Polaris Partners and ARCH Ventures.
• By
Emerging Company Profile: The Maryland-based biotech is working on a functional cure for type 1 diabetes that is similar to Vertex’s VX-880 – but with some key differences.
More from Start-Ups & SMEs
• By
The Biovelocita II fund is supported by the likes of Amgen, Bristol Myers Squibb and Pfizer
• By
CEO Adam Steensberg has led a major change in fortunes for the Danish biotech since March 2022.
• By
The Singapore and Seattle-based biotech is joining the race to bring a ‘double whammy’ antibody-drug conjugate to patients.